Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 58596 entries
Sorted by: Best Match Show Resources per page
Female representation in the academic oncology physician workforce: Radiation oncology losing ground to hematology oncology

Stem workforce diversity

Ahmed AA, Holliday EB, Hwang WT.
GSID: hmzaQ0BUzO0J
AA Ahmed, WT Hwang, EB Holliday… - International Journal of …, 2017 - Elsevier

Purpose Our purpose was to assess comparative female representation trends for trainees and full-time faculty in the academic radiation oncology and hematology oncology workforce of the United States over 3 decades. Methods and Materials Simple linear regression models with...

Cite
Ahmed, A. A., Hwang, W. T., Holliday, E. B., Chapman, C. H., Jagsi, R., Thomas Jr, C. R., & Deville Jr, C. (2017). Female representation in the academic oncology physician workforce: Radiation oncology losing ground to hematology oncology. International Journal of Radiation Oncology* Biology* Physics, 98(1), 31-33.
Ahmed, Awad A., et al. "Female representation in the academic oncology physician workforce: Radiation oncology losing ground to hematology oncology." International Journal of Radiation Oncology* Biology* Physics 98.1 (2017): 31-33.
Copy Download .nbib Format: MLA
Enhancing diversity in the hematology biomedical research workforce: A mentoring program to improve the odds of career success for early stage …

workforce diversity

Makala LH, Pace BS.
GSID: dP5PbHymrt4J
BS Pace, LH Makala, R Sarkar, L Liu… - American journal of …, 2017 - ncbi.nlm.nih.gov

The necessity for greater racial and ethnic diversity in the US biomedical research workforce is evident, however many challenges must be overcome to achieve this formidable goal …

Cite
Pace, B. S., Makala, L. H., Sarkar, R., Liu, L., Takezaki, M., Mohandas, N., ... & González, J. (2017). Enhancing diversity in the hematology biomedical research workforce: A mentoring program to improve the odds of career success for early stage investigators. American journal of hematology, 92(12), 1275.
Pace, Betty S., et al. "Enhancing diversity in the hematology biomedical research workforce: A mentoring program to improve the odds of career success for early stage investigators." American journal of hematology 92.12 (2017): 1275.
Copy Download .nbib Format: MLA
Career paths and workforce diversity in hematology: A cross-sectional study of a 35-year alumni cohort from an academic residency program in Brazil

Stem workforce diversity

De EV, Duarte BKL.
GSID: MZXMz2XzxUsJ
ACN Barbosa, BKL Duarte, EV De Paula - Hematology, Transfusion and …, 2022 - Elsevier

Introduction Although not mandatory, medical residency has become a sine qua non condition for practicing in most medical specialties in Brazil. Residency programs are hosted mainly by university accredited academic centers and hospitals in the national public healthcare system,...

Cite
Barbosa, A. C. N., Duarte, B. K. L., & De Paula, E. V. (2022). Career paths and workforce diversity in hematology: A cross-sectional study of a 35-year alumni cohort from an academic residency program in Brazil. Hematology, Transfusion and Cell Therapy.
Barbosa, Ayla Cristina Nóbrega, Bruno Kosa Lino Duarte, and Erich Vinicius De Paula. "Career paths and workforce diversity in hematology: A cross-sectional study of a 35-year alumni cohort from an academic residency program in Brazil." Hematology, Transfusion and Cell Therapy (2022).
Copy Download .nbib Format: MLA
The American Society of Pediatric Hematology/Oncology workforce assessment: part 1—current state of the workforce

Stem workforce diversity

[No authors listed]
GSID: hu4lCxJDhCwJ
, … Pediatric Hematology/Oncology Workforce … - Pediatric blood & …, 2018 - Wiley Online Library

Abstract The American Society of Pediatric Hematology/Oncology (ASPHO) recognized recent changes in medical practice and the potential impact on pediatric hematology–oncology (PHO) workforce. ASPHO surveyed society members and PHO Division Directors between 2010 and 2016 and studied PHO workforce...

Cite
Hord, J., Shah, M., Badawy, S. M., Matthews, D., Hilden, J., Wayne, A. S., ... & American Society of Pediatric Hematology/Oncology Workforce Advisory Taskforce. (2018). The American Society of Pediatric Hematology/Oncology workforce assessment: part 1—current state of the workforce. Pediatric blood & cancer, 65(2), e26780.
Hord, Jeffrey, et al. "The American Society of Pediatric Hematology/Oncology workforce assessment: part 1—current state of the workforce." Pediatric blood & cancer 65.2 (2018): e26780.
Copy Download .nbib Format: MLA
Complexities of classifying patients with Hodgkin disease: a plea for a prognostic index.

American journal of hematology

Schilling RF.
PMID: 655161
Am J Hematol. 1978;4(1):93-5. doi: 10.1002/ajh.2830040112.

No abstract available.

Cite
Schilling RF. Complexities of classifying patients with Hodgkin disease: a plea for a prognostic index. Am J Hematol. 1978;4(1):93-5doi: 10.1002/ajh.2830040112.
Schilling, R. F. (1978). Complexities of classifying patients with Hodgkin disease: a plea for a prognostic index. American journal of hematology, 4(1), 93-5. https://doi.org/10.1002/ajh.2830040112
Schilling, R F. "Complexities of classifying patients with Hodgkin disease: a plea for a prognostic index." American journal of hematology vol. 4,1 (1978): 93-5. doi: https://doi.org/10.1002/ajh.2830040112
Schilling RF. Complexities of classifying patients with Hodgkin disease: a plea for a prognostic index. Am J Hematol. 1978;4(1):93-5. doi: 10.1002/ajh.2830040112. PMID: 655161.
Copy Download .nbib Format: NLM
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.

Frontiers in immunology

Basner-Tschakarjan E, Mingozzi F.
PMID: 25101090
Front Immunol. 2014 Jul 23;5:350. doi: 10.3389/fimmu.2014.00350. eCollection 2014.

Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of gene...

Cite
Basner-Tschakarjan E, Mingozzi F. Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Front Immunol. 2014;5:350doi: 10.3389/fimmu.2014.00350.
Basner-Tschakarjan, E., & Mingozzi, F. (2014). Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Frontiers in immunology, 5350. https://doi.org/10.3389/fimmu.2014.00350
Basner-Tschakarjan, Etiena, and Mingozzi, Federico. "Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions." Frontiers in immunology vol. 5 (2014): 350. doi: https://doi.org/10.3389/fimmu.2014.00350
Basner-Tschakarjan E, Mingozzi F. Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Front Immunol. 2014 Jul 23;5:350. doi: 10.3389/fimmu.2014.00350. eCollection 2014. PMID: 25101090; PMCID: PMC4107954.
Copy Download .nbib Format: NLM
Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.

Letters in drug design & discovery

Gramling S, Reisman D.
PMID: 23565070
Lett Drug Des Discov. 2011 Jan 01;8(1):93-99. doi: 10.2174/157018011793663840.

Drug discovery in the field of oncology has been advanced mainly through the targeting of receptor tyrosine kinases. Both antibodies and small molecule inhibitors have been found to have successful applications in blocking the proliferative functions of these cell...

Cite
Gramling S, Reisman D. Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene. Lett Drug Des Discov. 2011;8(1):93-99doi: 10.2174/157018011793663840.
Gramling, S., & Reisman, D. (2011). Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene. Letters in drug design & discovery, 8(1), 93-99. https://doi.org/10.2174/157018011793663840
Gramling, Sarah, and Reisman, David. "Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene." Letters in drug design & discovery vol. 8,1 (2011): 93-99. doi: https://doi.org/10.2174/157018011793663840
Gramling S, Reisman D. Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene. Lett Drug Des Discov. 2011 Jan 01;8(1):93-99. doi: 10.2174/157018011793663840. PMID: 23565070; PMCID: PMC3615482.
Copy Download .nbib Format: NLM
Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.

International journal of hepatology

Venepalli NK, Goff L.
PMID: 23606971
Int J Hepatol. 2013;2013:341636. doi: 10.1155/2013/341636. Epub 2013 Mar 31.

Under normal physiological conditions, the hepatocyte growth factor (HGF) and its receptor, the MET transmembrane tyrosine kinase (cMET), are involved in embryogenesis, morphogenesis, and wound healing. The HGF-cMET axis promotes cell survival, proliferation, migration, and invasion via modulation of...

Cite
Venepalli NK, Goff L. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:341636doi: 10.1155/2013/341636.
Venepalli, N. K., & Goff, L. (2013). Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. International journal of hepatology, 2013341636. https://doi.org/10.1155/2013/341636
Venepalli, Neeta K, and Goff, Laura. "Targeting the HGF-cMET Axis in Hepatocellular Carcinoma." International journal of hepatology vol. 2013 (2013): 341636. doi: https://doi.org/10.1155/2013/341636
Venepalli NK, Goff L. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:341636. doi: 10.1155/2013/341636. Epub 2013 Mar 31. PMID: 23606971; PMCID: PMC3626399.
Copy Download .nbib Format: NLM
Overcoming AC220 resistance of FLT3-ITD by SAR302503.

Blood cancer journal

Kesarwani M, Huber E, Azam M.
PMID: 23995047
Blood Cancer J. 2013 Aug 30;3:e138. doi: 10.1038/bcj.2013.40.

No abstract available.

Cite
Kesarwani M, Huber E, Azam M. Overcoming AC220 resistance of FLT3-ITD by SAR302503. Blood Cancer J. 2013;3:e138doi: 10.1038/bcj.2013.40.
Kesarwani, M., Huber, E., & Azam, M. (2013). Overcoming AC220 resistance of FLT3-ITD by SAR302503. Blood cancer journal, 3e138. https://doi.org/10.1038/bcj.2013.40
Kesarwani, M, et al. "Overcoming AC220 resistance of FLT3-ITD by SAR302503." Blood cancer journal vol. 3 (2013): e138. doi: https://doi.org/10.1038/bcj.2013.40
Kesarwani M, Huber E, Azam M. Overcoming AC220 resistance of FLT3-ITD by SAR302503. Blood Cancer J. 2013 Aug 30;3:e138. doi: 10.1038/bcj.2013.40. PMID: 23995047; PMCID: PMC3763391.
Copy Download .nbib Format: NLM
Toll-like receptor 9 in breast cancer.

Frontiers in immunology

Sandholm J, Selander KS.
PMID: 25101078
Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014.

Toll-like receptor 9 (TLR9) is a cellular DNA receptor of the innate immune system. DNA recognition via TLR9 results in an inflammatory reaction, which eventually also activates a Th1-biased adaptive immune attack. In addition to cells of the immune...

Cite
Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol. 2014;5:330doi: 10.3389/fimmu.2014.00330.
Sandholm, J., & Selander, K. S. (2014). Toll-like receptor 9 in breast cancer. Frontiers in immunology, 5330. https://doi.org/10.3389/fimmu.2014.00330
Sandholm, Jouko, and Selander, Katri S. "Toll-like receptor 9 in breast cancer." Frontiers in immunology vol. 5 (2014): 330. doi: https://doi.org/10.3389/fimmu.2014.00330
Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014. PMID: 25101078; PMCID: PMC4105583.
Copy Download .nbib Format: NLM
Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndrome.

Frontiers in immunology

O'Connell AE, Volpi S, Dobbs K, Fiorini C, Tsitsikov E, de Boer H, Barlan IB, Despotovic JM, Espinosa-Rosales FJ, Hanson IC, Kanariou MG, Martínez-Beckerat R, Mayorga-Sirera A, Mejia-Carvajal C, Radwan N, Weiss AR, Pai SY, Lee YN, Notarangelo LD.
PMID: 25101082
Front Immunol. 2014 Jul 18;5:340. doi: 10.3389/fimmu.2014.00340. eCollection 2014.

The Wiskott-Aldrich syndrome (WAS) is due to mutations of the WAS gene encoding for the cytoskeletal WAS protein, leading to abnormal downstream signaling from the T cell and B cell antigen receptors (TCR and BCR). We hypothesized that the...

Cite
O'Connell AE, Volpi S, Dobbs K, et al. Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndrome. Front Immunol. 2014;5:340doi: 10.3389/fimmu.2014.00340.
O'Connell, A. E., Volpi, S., Dobbs, K., Fiorini, C., Tsitsikov, E., de Boer, H., Barlan, I. B., Despotovic, J. M., Espinosa-Rosales, F. J., Hanson, I. C., Kanariou, M. G., Martínez-Beckerat, R., Mayorga-Sirera, A., Mejia-Carvajal, C., Radwan, N., Weiss, A. R., Pai, S. Y., Lee, Y. N., & Notarangelo, L. D. (2014). Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndrome. Frontiers in immunology, 5340. https://doi.org/10.3389/fimmu.2014.00340
O'Connell, Amy E, et al. "Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndrome." Frontiers in immunology vol. 5 (2014): 340. doi: https://doi.org/10.3389/fimmu.2014.00340
O'Connell AE, Volpi S, Dobbs K, Fiorini C, Tsitsikov E, de Boer H, Barlan IB, Despotovic JM, Espinosa-Rosales FJ, Hanson IC, Kanariou MG, Martínez-Beckerat R, Mayorga-Sirera A, Mejia-Carvajal C, Radwan N, Weiss AR, Pai SY, Lee YN, Notarangelo LD. Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndrome. Front Immunol. 2014 Jul 18;5:340. doi: 10.3389/fimmu.2014.00340. eCollection 2014. PMID: 25101082; PMCID: PMC4102881.
Copy Download .nbib Format: NLM
Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101.

Journal of oncology

Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, Wipf P, Coplan JD, Chrico W, Joseph D, Brodsky JL, Batuman O.
PMID: 21977030
J Oncol. 2011;2011:232037. doi: 10.1155/2011/232037. Epub 2011 Sep 29.

Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, primarily due to the treatment-refractory/resistant nature of the disease. A rational approach to this compelling challenge is to develop new drugs that act synergistically with existing...

Cite
Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol. 2011;2011:232037doi: 10.1155/2011/232037.
Braunstein, M. J., Scott, S. S., Scott, C. M., Behrman, S., Walter, P., Wipf, P., Coplan, J. D., Chrico, W., Joseph, D., Brodsky, J. L., & Batuman, O. (2011). Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. Journal of oncology, 2011232037. https://doi.org/10.1155/2011/232037
Braunstein, Marc J, et al. "Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101." Journal of oncology vol. 2011 (2011): 232037. doi: https://doi.org/10.1155/2011/232037
Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, Wipf P, Coplan JD, Chrico W, Joseph D, Brodsky JL, Batuman O. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol. 2011;2011:232037. doi: 10.1155/2011/232037. Epub 2011 Sep 29. PMID: 21977030; PMCID: PMC3184436.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 58596 entries